{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:10:21Z","timestamp":1779880221265,"version":"3.53.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,27]]},"DOI":"10.7759\/cureus.109731","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:48:42Z","timestamp":1779878922000},"source":"Crossref","is-referenced-by-count":0,"title":["Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)\/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications"],"prefix":"10.7759","author":[{"given":"Cici","family":"McGuane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosha","family":"Farhadhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khavir A","family":"Sharieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N","family":"Petrosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Alabasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Adult obesity facts. (2024). Accessed. May 14 2025: https:\/\/www.cdc.gov\/obesity\/adult-obesity-facts\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase E","year":"2024","unstructured":"Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024, 386:q1645. 10.1136\/bmj.q1645","journal-title":"BMJ"},{"key":"ref3","unstructured":"KFF health tracking poll May 2024. The public\u2019s use and views of GLP-1 drugs. (2024). Accessed: October 20th, 2025: https:\/\/www.kff.org\/health-costs\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24336","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the obesity Medicine Association, and the Obesity Society","volume":"33","author":"Mozaffarian D","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et al.. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the obesity Medicine Association, and the Obesity Society. Obesity (Silver Spring). 2025, 33:1475-503. 10.1002\/oby.24336","journal-title":"Obesity (Silver Spring)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre J","year":"1973","unstructured":"Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973, 37:826-8. 10.1210\/jcem-37-5-826","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415550121","article-title":"The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity","volume":"121","author":"Friedman JM","year":"2024","unstructured":"Friedman JM. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proc Natl Acad Sci U S A. 2024, 121:e2415550121. 10.1073\/pnas.2415550121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck MA","year":"2023","unstructured":"Nauck MA, M\u00fcller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023, 66:1780-95. 10.1007\/s00125-023-05956-x","journal-title":"Diabetologia"},{"key":"ref8","unstructured":"Byetta highlights of prescribing information. (2005). Accessed. October 15, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021773s9s11s18s22s25lbl.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050459","article-title":"Exenatide","volume":"63","author":"Bray GM","year":"2006","unstructured":"Bray GM. Exenatide. Am J Health Syst Pharm. 2006, 63:411-8. 10.2146\/ajhp050459","journal-title":"Am J Health Syst Pharm"},{"key":"ref10","unstructured":"Victoza highlights of precribing information. (2010). Accessed. October 15, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse JB","year":"2004","unstructured":"Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004, 27:2628-35. 10.2337\/diacare.27.11.2628","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01673.x","article-title":"Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme","volume":"15","author":"Niswender K","year":"2013","unstructured":"Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013, 15:42-54. 10.1111\/j.1463-1326.2012.01673.x","journal-title":"Diabetes Obes Metab"},{"key":"ref13","unstructured":"Obesity and overweight. Developing drugs and biological products for weight reduction guidance for industry. (2025). Accessed: October 15, 2025: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/obesity-and-overweight-developing-drugs-and-...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer X","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015, 373:11-22. 10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"ref15","unstructured":"Saxenda highlights of prescribing information. (2014). Accessed. October 11, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321orig1s000lbl.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref17","unstructured":"Wegovy highlights of prescribing information. (2021). Accessed. October 12, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf."},{"key":"ref18","unstructured":"Mounjaro highlights of prescribing information. (2022). Accessed. October 12, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref20","unstructured":"Zepbound Highlights of Prescribing Information. (2022). Accessed. October 13, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217806s000lbl.pdf."},{"key":"ref21","article-title":"Pharmacologic therapy for obesity(Archived)","author":"Rodrigues Silva Sombra L","year":"2024","unstructured":"Rodrigues Silva Sombra L, Anastasopoulou C. Pharmacologic therapy for obesity(Archived). StatPearls [Internet]. Sombra LRS, Anastasopoulou C (ed): StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min JS","year":"2025","unstructured":"Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist. Drug Des Devel Ther. 2025, 19:3509-37. 10.2147\/DDDT.S506957","journal-title":"Drug Des Devel Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz A","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025, 138:934-40. 10.1016\/j.amjmed.2025.01.021","journal-title":"Am J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02006","article-title":"Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans","volume":"103","author":"Halim MA","year":"2018","unstructured":"Halim MA, Degerblad M, Sundbom M, Karlbom U, Holst JJ, Webb DL, Hellstr\u00f6m PM. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. J Clin Endocrinol Metab. 2018, 103:575-85. 10.1210\/jc.2017-02006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15603","article-title":"Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating","volume":"179","author":"Brierley DI","year":"2022","unstructured":"Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol. 2022, 179:584-99. 10.1111\/bph.15603","journal-title":"Br J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14166","article-title":"Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying","volume":"22","author":"Horowitz M","year":"2020","unstructured":"Horowitz M, Rayner CK, Marathe CS, Wu T, Jones KL. Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying. Diabetes Obes Metab. 2020, 22:2504-6. 10.1111\/dom.14166","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002820","article-title":"Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management","volume":"119","author":"Hiramoto B","year":"2024","unstructured":"Hiramoto B, McCarty TR, Lodhia NA, et al.. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol. 2024, 119:1126-40. 10.14309\/ajg.0000000000002820","journal-title":"Am J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck MA","year":"2011","unstructured":"Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011, 60:1561-5. 10.2337\/db10-0474","journal-title":"Diabetes"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al.. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024, 110:1-15. 10.1210\/clinem\/dgae719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3945\/jn.114.206029","article-title":"Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling","volume":"145","author":"Ronveaux CC","year":"2015","unstructured":"Ronveaux CC, Tom\u00e9 D, Raybould HE. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr. 2015, 145:672-80. 10.3945\/jn.114.206029","journal-title":"J Nutr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh H","year":"2020","unstructured":"Kadouh H, Chedid V, Halawi H, et al.. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020, 105:1552-63. 10.1210\/clinem\/dgz140","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12533","article-title":"GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects","volume":"17","author":"Lin J","year":"2015","unstructured":"Lin J, Hodge RJ, O'Connor-Semmes RL, Nunez DJ. GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects. Diabetes Obes Metab. 2015, 17:1007-10. 10.1111\/dom.12533","journal-title":"Diabetes Obes Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"Rehfeld JF","year":"2018","unstructured":"Rehfeld JF, Knop FK, Asmar A, Madsbad S, Holst JJ, Asmar M. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol. 2018, 53:1429-32. 10.1080\/00365521.2018.1530297","journal-title":"Scand J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2442027","article-title":"Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials","volume":"41","author":"Rivera FB","year":"2025","unstructured":"Rivera FB, Chin MN, Pine PL, et al.. Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials. Curr Med Res Opin. 2025, 41:185-97. 10.1080\/03007995.2024.2442027","journal-title":"Curr Med Res Opin"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0302","article-title":"GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK","volume":"63","author":"Beiroa D","year":"2014","unstructured":"Beiroa D, Imbernon M, Gallego R, et al.. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014, 63:3346-58. 10.2337\/db14-0302","journal-title":"Diabetes"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi SH","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024, 15:20420188231222367. 10.1177\/20420188231222367","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45060288","article-title":"The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD","volume":"45","author":"Petrovic A","year":"2023","unstructured":"Petrovic A, Igrec D, Rozac K, et al.. The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD. Curr Issues Mol Biol. 2023, 45:4544-56. 10.3390\/cimb45060288","journal-title":"Curr Issues Mol Biol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu QK","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024, 15:1431292. 10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177966","article-title":"The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight\/obesity: an umbrella review of systematic reviews and meta-analyses","volume":"1003","author":"Zamanian N","year":"2025","unstructured":"Zamanian N, Imani H, Talebi S, Rahimlou M, Khosroshahi RA, Mohammadi H. The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight\/obesity: an umbrella review of systematic reviews and meta-analyses. Eur J Pharmacol. 2025, 1003:177966. 10.1016\/j.ejphar.2025.177966","journal-title":"Eur J Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study","volume":"37","author":"Wadden TA","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013, 37:1443-51. 10.1038\/ijo.2013.120","journal-title":"Int J Obes (Lond)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden TA","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021, 325:1403-13. 10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino D","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325:1414-25. 10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey WT","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022, 28:2083-91. 10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02883-1","article-title":"Author correction: tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"30","author":"Wadden TA","year":"2024","unstructured":"Wadden TA, Chao AM, Machineni S, et al.. Author correction: tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2024, 30:1784. 10.1038\/s41591-024-02883-1","journal-title":"Nat Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde KM","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, et al.. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377:1341-1352. 10.1016\/S0140-6736(11)60205-5","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz A","year":"2025","unstructured":"Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann Intern Med. 2025, 178:199-217. 10.7326\/ANNALS-24-01590","journal-title":"Ann Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn W","year":"2024","unstructured":"Ghusn W, Hurtado MD. Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024, 12:100127. 10.1016\/j.obpill.2024.100127","journal-title":"Obes Pillars"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA Adverse Event Reporting System database","volume":"42","author":"Wu T","year":"2022","unstructured":"Wu T, Zhang Y, Shi Y, Yu K, Zhao M, Liu S, Zhao Z. Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA Adverse Event Reporting System database. Clin Drug Investig. 2022, 42:965-75. 10.1007\/s40261-022-01202-1","journal-title":"Clin Drug Investig"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"Kim JA","year":"2025","unstructured":"Kim JA, Yoo HJ. Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning. Diabetes Metab J. 2025, 49:525-41. 10.4093\/dmj.2025.0242","journal-title":"Diabetes Metab J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell L","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006, 29:385-96. 10.2165\/00002018-200629050-00003","journal-title":"Drug Saf"},{"key":"ref53","article-title":"Semaglutide and tirzepatide for obesity: effectiveness and value","author":"Lin GA","year":"2025","unstructured":"Lin GA, Lee W, Fahim SM, et al.. Semaglutide and tirzepatide for obesity: effectiveness and value. Institute for clinical and economic review. 2025,","journal-title":"Institute for clinical and economic review"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2025.3590","article-title":"Obesity treatment with bariatric surgery vs GLP-1 receptor agonists","volume":"160","author":"Barrett TS","year":"2025","unstructured":"Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. Obesity treatment with bariatric surgery vs GLP-1 receptor agonists. JAMA Surg. 2025, 160:1232-9. 10.1001\/jamasurg.2025.3590","journal-title":"JAMA Surg"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield SB","year":"2014","unstructured":"Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014, 15:310-21. 10.1111\/obr.12143","journal-title":"Obes Rev"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23910","article-title":"Proportion of caloric restriction-induced weight loss as skeletal muscle","volume":"32","author":"Heymsfield SB","year":"2024","unstructured":"Heymsfield SB, Yang S, McCarthy C, et al.. Proportion of caloric restriction-induced weight loss as skeletal muscle. Obesity (Silver Spring). 2024, 32:32-40. 10.1002\/oby.23910","journal-title":"Obesity (Silver Spring)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13916","article-title":"How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis","volume":"26","author":"Anyiam O","year":"2025","unstructured":"Anyiam O, Ardavani A, Rashid RS, Panesar A, Idris I. How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis. Obes Rev. 2025, 26:e13916. 10.1111\/obr.13916","journal-title":"Obes Rev"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26 Suppl 4","author":"Neeland IJ","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024, 26 Suppl 4:16-27. 10.1111\/dom.15728","journal-title":"Diabetes Obes Metab"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck MA","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, et al.. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet . 2026, 407:892-908. 10.1016\/S0140-6736(25)02105-1","journal-title":"Lancet"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker DJ","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024, 47:1873-88. 10.2337\/dci24-0003","journal-title":"Diabetes Care"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf110","article-title":"GLP-1-based therapeutics for cardiorenal protection in metabolic diseases","volume":"41","author":"Apperloo EM","year":"2026","unstructured":"Apperloo EM, Heerspink HJ, van Raalte DH, Muskiet MH. GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. Nephrol Dial Transplant. 2026, 41:207-19. 10.1093\/ndt\/gfaf110","journal-title":"Nephrol Dial Transplant"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz A","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025, 86:103363. 10.1016\/j.eclinm.2025.103363","journal-title":"EClinicalMedicine"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.14392","article-title":"New molecules and indications for GLP-1 medicines","volume":"334","author":"Gonzalez-Rellan MJ","year":"2025","unstructured":"Gonzalez-Rellan MJ, Drucker DJ. New molecules and indications for GLP-1 medicines. JAMA. 2025, 334:1231-4. 10.1001\/jama.2025.14392","journal-title":"JAMA"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.056","article-title":"Diabetic agents, from metformin to\u00a0SGLT2 inhibitors and GLP1\u00a0receptor\u00a0agonists: JACC focus seminar","volume":"75","author":"Wilcox T","year":"2020","unstructured":"Wilcox T, De Block C, Schwartzbard AZ, Newman JD. Diabetic agents, from metformin to\u00a0SGLT2 inhibitors and GLP1\u00a0receptor\u00a0agonists: JACC focus seminar. J Am Coll Cardiol. 2020, 75:1956-74. 10.1016\/j.jacc.2020.02.056","journal-title":"J Am Coll Cardiol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1566498","article-title":"Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study","volume":"12","author":"Johnson B","year":"2025","unstructured":"Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R, Jones R. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr. 2025, 12:1566498. 10.3389\/fnut.2025.1566498","journal-title":"Front Nutr"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100186","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study","volume":"15","author":"Scott Butsch W","year":"2025","unstructured":"Scott Butsch W, Sulo S, Chang AT, et al.. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes Pillars. 2025, 15:100186. 10.1016\/j.obpill.2025.100186","journal-title":"Obes Pillars"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2174\/1573399818666220418080959","article-title":"Metformin-induced vitamin B12 deficiency among type 2 diabetes mellitus\u2019 patients: a systematic review","volume":"19","author":"Khattab R","year":"2023","unstructured":"Khattab R, Albannawi M, Alhajjmohammed D, et al.. Metformin-induced vitamin B12 deficiency among type 2 diabetes mellitus\u2019 patients: a systematic review. Curr Diabetes Rev. 2023, 19:e180422203716. 10.2174\/1573399818666220418080959","journal-title":"Curr Diabetes Rev"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2025.104193","article-title":"Metformin is associated with low levels of vitamin B12 with no effect on other vitamin levels. A selective action of metformin","volume":"35","author":"Vigolo N","year":"2025","unstructured":"Vigolo N, Toffalini A, Rolli N, et al.. Metformin is associated with low levels of vitamin B12 with no effect on other vitamin levels. A selective action of metformin. Nutr Metab Cardiovasc Dis. 2025, 35:104193. 10.1016\/j.numecd.2025.104193","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100121","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen S","year":"2024","unstructured":"Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs. Obes Pillars. 2024, 11:100121. 10.1016\/j.obpill.2024.100121","journal-title":"Obes Pillars"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3390\/nu17111934","article-title":"Unintended consequences of obesity pharmacotherapy: a nutritional approach to ensuring better patient outcomes","volume":"17","author":"Al-Najim W","year":"2025","unstructured":"Al-Najim W, Raposo A, BinMowyna MN, le Roux CW. Unintended consequences of obesity pharmacotherapy: a nutritional approach to ensuring better patient outcomes. Nutrients. 2025, 17:10.3390\/nu17111934","journal-title":"Nutrients"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14477","article-title":"Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes","volume":"23","author":"Quast DR","year":"2021","unstructured":"Quast DR, Nauck MA, Schenker N, Menge BA, Kapitza C, Meier JJ. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab. 2021, 23:2344-53. 10.1111\/dom.14477","journal-title":"Diabetes Obes Metab"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70063","article-title":"Impact of tirzepatide treatment on participant-reported food craving and food preference: secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction","volume":"27","author":"Kennedy SF","year":"2025","unstructured":"Kennedy SF, Knights A, Ravussin E, et al.. Impact of tirzepatide treatment on participant-reported food craving and food preference: secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction. Diabetes Obes Metab. 2025, 27:6784-9. 10.1111\/dom.70063","journal-title":"Diabetes Obes Metab"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin CK","year":"2025","unstructured":"Martin CK, Carmichael OT, Carnell S, et al.. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025, 31:3141-50. 10.1038\/s41591-025-03774-9","journal-title":"Nat Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can J","year":"2014","unstructured":"van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014, 38:784-93. 10.1038\/ijo.2013.162","journal-title":"Int J Obes (Lond)"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen M","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021, 23:754-62. 10.1111\/dom.14280","journal-title":"Diabetes Obes Metab"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell J","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017, 19:1242-51. 10.1111\/dom.12932","journal-title":"Diabetes Obes Metab"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1159\/000519503","article-title":"Malnutrition in obesity: is it possible?","volume":"15","author":"Kobyli\u0144ska M","year":"2022","unstructured":"Kobyli\u0144ska M, Antosik K, Decyk A, Kurowska K. Malnutrition in obesity: is it possible?. Obes Facts. 2022, 15:19-25. 10.1159\/000519503","journal-title":"Obes Facts"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-018-0143-9","article-title":"Overfed but undernourished: recognizing nutritional inadequacies\/deficiencies in patients with overweight or obesity","volume":"43","author":"Astrup A","year":"2019","unstructured":"Astrup A, B\u00fcgel S. Overfed but undernourished: recognizing nutritional inadequacies\/deficiencies in patients with overweight or obesity. Int J Obes (Lond). 2019, 43:219-32. 10.1038\/s41366-018-0143-9","journal-title":"Int J Obes (Lond)"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2014.901196","article-title":"Comparison of prevalence of inadequate nutrient intake based on body weight status of adults in the United States: an analysis of NHANES 2001-2008","volume":"34","author":"Agarwal S","year":"2015","unstructured":"Agarwal S, Reider C, Brooks JR, Fulgoni VL 3rd. Comparison of prevalence of inadequate nutrient intake based on body weight status of adults in the United States: an analysis of NHANES 2001-2008. J Am Coll Nutr. 2015, 34:126-34. 10.1080\/07315724.2014.901196","journal-title":"J Am Coll Nutr"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2017.10.002","article-title":"Academy of Nutrition and Dietetics: revised 2017 scope of practice for the registered dietitian nutritionist","volume":"118","author":"Academy Quality Management Committee","year":"2018","unstructured":"Academy Quality Management Committee. Academy of Nutrition and Dietetics: revised 2017 scope of practice for the registered dietitian nutritionist. J Acad Nutr Diet. 2018, 118:141-65. 10.1016\/j.jand.2017.10.002","journal-title":"J Acad Nutr Diet"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00070.2021","article-title":"Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity","volume":"321","author":"Kunz HE","year":"2021","unstructured":"Kunz HE, Hart CR, Gries KJ, et al.. Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity. Am J Physiol Endocrinol Metab. 2021, 321:E105-21. 10.1152\/ajpendo.00070.2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref82","article-title":"Risk of malnutrition and nutritional considerations for patient on surgical and medically prescribed weight loss therapies","author":"Kobyli\u0144ska M","year":"2024","unstructured":"Kobyli\u0144ska M, Antosik K, Decyk A, et al.. Risk of malnutrition and nutritional considerations for patient on surgical and medically prescribed weight loss therapies. American Society for parenteral and enteral l nutrition. 2024,","journal-title":"American Society for parenteral and enteral l nutrition"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez JJ","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al.. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022, 12:10.3390\/jcm12010145","journal-title":"J Clin Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.11153","article-title":"Managing adverse effects of incretin-based medications for obesity","volume":"334","author":"Kushner RF","year":"2025","unstructured":"Kushner RF, Almandoz JP, Rubino DM. Managing adverse effects of incretin-based medications for obesity. JAMA. 2025, 334:822-3. 10.1001\/jama.2025.11153","journal-title":"JAMA"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.1794","article-title":"Integrating diet and physical activity when prescribing GLP-1s-lifestyle factors remain crucial","volume":"185","author":"Mehrtash F","year":"2025","unstructured":"Mehrtash F, Dushay J, Manson JE. Integrating diet and physical activity when prescribing GLP-1s-lifestyle factors remain crucial. JAMA Intern Med. 2025, 185:1151-2. 10.1001\/jamainternmed.2025.1794","journal-title":"JAMA Intern Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3390\/life15060843","article-title":"Bidirectional interactions between the gut microbiota and incretin-based therapies","volume":"15","author":"Trapanese V","year":"2025","unstructured":"Trapanese V, Dagostino A, Natale MR, et al.. Bidirectional interactions between the gut microbiota and incretin-based therapies. Life (Basel). 2025, 15:10.3390\/life15060843","journal-title":"Life (Basel)"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.3390\/nu17081303","article-title":"Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review","volume":"17","author":"Gofron KK","year":"2025","unstructured":"Gofron KK, Wasilewski A, Ma\u0142gorzewicz S. Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review. Nutrients. 2025, 17:10.3390\/nu17081303","journal-title":"Nutrients"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113791","article-title":"Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies","volume":"14","author":"Quarenghi M","year":"2025","unstructured":"Quarenghi M, Capelli S, Galligani G, Giana A, Preatoni G, Turri Quarenghi R. Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies. J Clin Med. 2025, 14:10.3390\/jcm14113791","journal-title":"J Clin Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"26","author":"Berg S","year":"2025","unstructured":"Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis. Obes Rev. 2025, 26:e13929. 10.1111\/obr.13929","journal-title":"Obes Rev"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100143","article-title":"Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: a qualitative research study with registered dietitians","volume":"12","author":"Despain D","year":"2024","unstructured":"Despain D, Hoffman BL. Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: a qualitative research study with registered dietitians. Obes Pillars. 2024, 12:100143. 10.1016\/j.obpill.2024.100143","journal-title":"Obes Pillars"},{"key":"ref91","article-title":"Clinical management of obesity","author":"Apovian MD","year":"2016","unstructured":"Apovian MD, Aronne L, Barenbaum SR, et al.. Clinical management of obesity. Apovian MD, Aronne L, Barenbaum SR, et al. (ed): Professional Communications Inc., West Islip, NY; 2016."},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2021.05.026","article-title":"Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: revised 2021 standards of practice and standards of professional performance for registered dietitian nutritionists (competent, proficient, and expert) in nutrition support","volume":"121","author":"Corrigan ML","year":"2021","unstructured":"Corrigan ML, Bobo E, Rollins C, Mogensen KM. Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: revised 2021 standards of practice and standards of professional performance for registered dietitian nutritionists (competent, proficient, and expert) in nutrition support. J Acad Nutr Diet. 2021, 121:2071-2086.e59. 10.1016\/j.jand.2021.05.026","journal-title":"J Acad Nutr Diet"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdnut.2024.104486","article-title":"Sculpting success: The importance of diet and physical activity to support skeletal muscle health during weight loss with new generation anti-obesity medications","volume":"8","author":"Grosicki GJ","year":"2024","unstructured":"Grosicki GJ, Dhurandhar NV, Unick JL, et al.. Sculpting success: The importance of diet and physical activity to support skeletal muscle health during weight loss with new generation anti-obesity medications. Curr Dev Nutr. 2024, 8:104486. 10.1016\/j.cdnut.2024.104486","journal-title":"Curr Dev Nutr"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy KL","year":"2018","unstructured":"Piercy KL, Troiano RP, Ballard RM, et al.. The physical activity guidelines for Americans. JAMA. 2018, 320:2020-8. 10.1001\/jama.2018.14854","journal-title":"JAMA"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0b013e3181915670","article-title":"Progression models in resistance training for healthy adults","volume":"41","author":"American College of Sports Medicine","year":"2009","unstructured":"American College of Sports Medicine. Progression models in resistance training for healthy adults. Med Sci Sports Exerc. 2009, 41:687-708. 10.1249\/MSS.0b013e3181915670","journal-title":"Med Sci Sports Exerc"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S103649","article-title":"Weight loss intervention adherence and factors promoting adherence: a meta-analysis","volume":"10","author":"Lemstra M","year":"2016","unstructured":"Lemstra M, Bird Y, Nwankwo C, Rogers M, Moraros J. Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer Adherence. 2016, 10:1547-59. 10.2147\/PPA.S103649","journal-title":"Patient Prefer Adherence"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22 Suppl 3","author":"Garvey WT","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016, 22 Suppl 3:1-203. 10.4158\/EP161365.GL","journal-title":"Endocr Pract"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2015.10.031","article-title":"Position of the academy of nutrition and dietetics: interventions for the treatment of overweight and obesity in adults","volume":"116","author":"Raynor HA","year":"2016","unstructured":"Raynor HA, Champagne CM. Position of the academy of nutrition and dietetics: interventions for the treatment of overweight and obesity in adults. J Acad Nutr Diet. 2016, 116:129-47. 10.1016\/j.jand.2015.10.031","journal-title":"J Acad Nutr Diet"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8223(03)00971-4","article-title":"Nutrition care process and model: ADA adopts road map to quality care and outcomes management","volume":"103","author":"Lacey K","year":"2003","unstructured":"Lacey K, Pritchett E. Nutrition care process and model: ADA adopts road map to quality care and outcomes management. Journal of the American Dietetic Association. 2003, 103:1061-1072. 10.1016\/s0002-8223(03)00971-4","journal-title":"Journal of the American Dietetic Association"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.04.039","article-title":"AGA clinical practice update on evaluation and management of belching, abdominal bloating, and distention: expert review","volume":"165","author":"Moshiree B","year":"2023","unstructured":"Moshiree B, Drossman D, Shaukat A. AGA clinical practice update on evaluation and management of belching, abdominal bloating, and distention: expert review. Gastroenterology. 2023, 165:791-800.e3. 10.1053\/j.gastro.2023.04.039","journal-title":"Gastroenterology"},{"key":"ref101","article-title":"Evaluation and treatment of nausea and vomiting in adults","volume":"109","author":"Johns T","year":"2024","unstructured":"Johns T, Lawrence E. Evaluation and treatment of nausea and vomiting in adults. Am Fam Physician. 2024, 109:417-25.","journal-title":"Am Fam Physician"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease - 2025 update","volume":"31","author":"Nadolsky K","year":"2025","unstructured":"Nadolsky K, Garvey WT, Agarwal M, et al.. American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease - 2025 update. Endocr Pract. 2025, 31:1351-94. 10.1016\/j.eprac.2025.07.017","journal-title":"Endocr Pract"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti F","year":"2026","unstructured":"Celletti F, Farrar J, De Regil L. World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2026, 335:434-8. 10.1001\/jama.2025.24288","journal-title":"JAMA"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S008","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026. Diabetes Care. 2026, 49:S166-82. 10.2337\/dc26-S008","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/477348-nutritional-care-for-adults-with-obesity-treated-with-glucagon-like-peptide-glp-1-and-dual-glucose-dependent-insulinotropic-polypeptide-gipglp-1-receptor-agonists-a-review-of-evidence-gaps-and-clinical-implications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:48:45Z","timestamp":1779878925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/477348-nutritional-care-for-adults-with-obesity-treated-with-glucagon-like-peptide-glp-1-and-dual-glucose-dependent-insulinotropic-polypeptide-gipglp-1-receptor-agonists-a-review-of-evidence-gaps-and-clinical-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":104,"URL":"https:\/\/doi.org\/10.7759\/cureus.109731","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}